← Back to Clinical Trials
RecruitingNCT04578808

Unruptured Cerebral Aneurysm: Prediction of Evolution

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionUnruptured Intracranial Aneurysm
SponsorNantes University Hospital
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment1,000
SexALL
Min Age18 Years
Max AgeN/A
Start Date2019-08-19
Completion2029-03-15
Interventions
Unruptured intracranial aneurysms

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The protocol has many assets. A prospective nationwide recruitment allows for the inclusion of a large cohort of patients with UIA. It will combine accurate clinical phenotyping and comprehensive imaging with CAWE screening. Besides, it will enable to exploit metadata and to explore new pathophysiological pathways of interest by crossing clinical, genetic, biological, and imaging information.

Eligibility Criteria

Inclusion Criteria : * Subject carrying unruptured, asymptomatic and untreated typical IA of bifurcation, measured on conventional imaging (MRI, CTA or DSA) between 3 and 7 mm of larger diameter. * Ability to be followed-up during 3 years decided in consensus multidisciplinary gathering. * Age \> 18 years old. Exclusion Criteria : * A failure to obtain informed consent * Contraindications for undergoing an MRI scan include : (heart pacemaker, a metallic foreign body (metal sliver) in their eye, or aneurysm clip in their brain, severe claustrophobia) * Contraindications for a gadolinium contrast medium injection (:eGFR below 30 mL/min/1.73 m2, Previous or pre-existing nephrogenic systemic fibrosis, Previous anaphylactic/anaphylactoid reaction to gadolinium containing contrast agent, Acutely deteriorating renal function, Pregnancy and breast-feeding) * A mycotic, fusiform-shaped, or dissecting IA, an IA in relation with an arteriovenous malformation * A family history of polycystic kidne

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology